Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
In this article:
Shares in Bristol-Myers Squibb (BMY) rose Friday, after the Food and Drug Administration approved the drugmaker's novel treatment for schizophrenia. Bristol-Myers shares stood about 1.8% higher in Friday morning trading, at $51.